Clinical Report: Evaluation of Adjuvant Nivolumab in Patients with Resected Stage III–IV Melanoma
Overview
The AdjuMel study reports a 52.8% relapse-free survival rate at 2 years for patients with resected stage III–IV melanoma treated with adjuvant nivolumab. The safety profile remains consistent with previous studies.
Background
Melanoma incidence is increasing across Europe, with advanced stages associated with poorer survival rates. Nivolumab, an anti-PD-1 agent, is a recommended treatment for completely resected stage III–IV melanoma. Understanding real-world effectiveness and safety of nivolumab is crucial for optimizing treatment strategies.
Data Highlights
No numerical data table available.
Key Findings
At 2 years, the relapse-free survival rate was 52.8% for patients treated with adjuvant nivolumab.
Patients with stage IIIA disease had lower recurrence or death rates compared to those with stage IIIB–D disease.
Individuals aged < 75 years experienced fewer recurrences or deaths than those aged ≥ 75 years.
Tumor ulceration was linked to a higher risk of recurrence or death.
The safety profile of adjuvant nivolumab was consistent with earlier reports.
No adverse effects on health-related quality of life were observed.
Clinical Implications
The findings from the AdjuMel study provide insights into the effectiveness of nivolumab in a real-world setting.
Conclusion
The AdjuMel study contributes valuable data on the use of adjuvant nivolumab in routine clinical practice.
by Stéphane Dalle, Philippe Saiag, Céleste Lebbé, Jean-Jacques Grob, Brigitte Dréno, Sophie Dalac, Bernard Asselain, François Skowron, Sophie Darras, Nicolas Jovenin, Gaëlle Quereux, Amir Khammari, Capucine Rieuf, Florence Brellier, Laurent Mortier
he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
